Treatment of advanced melanoma: Past, present and future

Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Yusuke Muto, Setsuya Aiba

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)

Abstract

Therapeutic options for treating advanced melanoma are progressing rapidly. Until six years ago, the regimen for treating advanced melanoma mainly comprised cytotoxic agents such as dacarbazine, and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies have become recognized as anchor drugs for treating advanced melanoma with or without additional combination drugs such as ipilimumab. In addition, v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase inhibitors in combination with mitogen-activated protein kinase kinase (MEK) inhibitors are among the most promising chemotherapeutic regimens for treating advanced BRAF-mutant melanoma, especially in patients with low tumor burden. Since anti-PD1 antibodies are widely applicable for the treatment of both BRAF wild-type and mutated advanced melanomas, several clinical trials for drugs in combination with anti-PD1 antibodies are ongoing. This review focuses on the development of the anti-melanoma therapies available today, and discusses the clinical trials of novel regimens for the treatment of advanced melanoma.

Original languageEnglish
Article number208
Pages (from-to)1-15
Number of pages15
JournalLife
Volume10
Issue number9
DOIs
Publication statusPublished - 2020 Sep

Keywords

  • BRAF inhibitors
  • Combination therapy
  • Immune checkpoints inhibitors
  • MEK inhibitors
  • Metastatic melanoma

ASJC Scopus subject areas

  • Ecology, Evolution, Behavior and Systematics
  • Biochemistry, Genetics and Molecular Biology(all)
  • Space and Planetary Science
  • Palaeontology

Fingerprint Dive into the research topics of 'Treatment of advanced melanoma: Past, present and future'. Together they form a unique fingerprint.

Cite this